Advertisement

Circulating Tumor Cells

  • Costanza Paoletti
  • Daniel F. Hayes
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 882)

Abstract

Circulating Tumor Cells (CTC) are shed from primary or secondary tumors. Prior studies have demonstrated that enumeration of CTC is a robust independent prognostic factor of progression free and overall survival in patients with early and metastatic breast cancer. CTC, as well as other circulating tumor markers, have the appealing advantages over tissue biopsy of (1) ease of collection, (2) serial evaluation, and (3) interrogation of the entire tumor burden instead of just a limited part of the tumor. Advances have been recently made in phenotyping and genotyping of CTC, which should provide insights into the predictive role of CTC for sensitivity or resistance to therapies. In addition, CTC phenotypic marker changes during the course of treatment may serve as pharmacodynamic monitoring tools. Therefore, CTC may be considered “liquid biopsies,” providing prognostic and predictive clinical information as well as additional understanding of tumor heterogeneity.

Keywords

Circulating Tumor Cells (CTC) Breast cancer Enumeration Characterization Cluster Prognosis Prediction 

Notes

Acknowledgments

We gratefully acknowledge Celina Kleer, M.D. who provided the pathology images for Fig. 1.

References

  1. 1.
    Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564CrossRefPubMedGoogle Scholar
  2. 2.
    Ashworth TR (1869) A case of cancer in which cells similar to those tumours were seen in the blood after death. Med J Aust 14:146–147Google Scholar
  3. 3.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791CrossRefPubMedGoogle Scholar
  4. 4.
    Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489Google Scholar
  5. 5.
    Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D et al (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G et al (2012) Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 18:5701–5710CrossRefPubMedGoogle Scholar
  7. 7.
    Gertler R, Rosenberg R, Fuehrer K, Dahm M, Nekarda H, Siewert JR (2003) Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 162:149–155CrossRefPubMedGoogle Scholar
  8. 8.
    Gascoyne PR, Noshari J, Anderson TJ, Becker FF (2009) Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30:1388–1398CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zheng S (2007) Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A 1162:154–161CrossRefPubMedGoogle Scholar
  10. 10.
    Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156:57–63CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904CrossRefPubMedGoogle Scholar
  12. 12.
    Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W et al (2009) Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106:3970–3975CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:1235–1239CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Saliba AE, Saias L, Psychari E, Minc N, Simon D, Bidard FC et al (2010) Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays. Proc Natl Acad Sci U S A 107:14524–14529CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107:18392–18397CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT et al (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580–584CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yoon HJ, Kim TH, Zhang Z, Azizi E, Pham TM, Paoletti C et al (2013) Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 8:735–741CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152–8162CrossRefPubMedGoogle Scholar
  19. 19.
    Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F et al (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9:016003CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27:2177–2184CrossRefPubMedGoogle Scholar
  21. 21.
    Stathopoulou A (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20:3404–3412CrossRefPubMedGoogle Scholar
  22. 22.
    Ignatiadis M (2007) Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol 25:5194–5202CrossRefPubMedGoogle Scholar
  23. 23.
    Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S et al (2012) Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect versus Veridex CellSearch system. Int J Cancer 130:1590–1597CrossRefPubMedGoogle Scholar
  24. 24.
    Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A et al (2010) Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 102:276–284CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P et al (2012) A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 41:1241–1250PubMedPubMedCentralGoogle Scholar
  26. 26.
    Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N et al (2009) The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 11:3–14CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Micheel CM, Nass SJ, Omenn GS (2012). Evolution of translational omics: lessons learned and the path forward. The National Academies PressGoogle Scholar
  28. 28.
    Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Paoletti C, Hayes DF (2014) Molecular testing in breast cancer. Annu Rev Med 65:95–110CrossRefPubMedGoogle Scholar
  30. 30.
    Harris L (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312CrossRefPubMedGoogle Scholar
  31. 31.
    Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF et al (2011) NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9(Suppl 5):S1–32; quiz S3Google Scholar
  32. 32.
    Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB et al (2013) Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 11:753–760; quiz 61PubMedPubMedCentralGoogle Scholar
  33. 33.
    Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L et al (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688–695CrossRefPubMedGoogle Scholar
  34. 34.
    Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T et al (2014) Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 106:dju066 doi:10.1093/jnci/dju066Google Scholar
  35. 35.
    Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P et al (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21:729–733CrossRefPubMedGoogle Scholar
  36. 36.
    Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M et al (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16:2634–2645CrossRefPubMedGoogle Scholar
  37. 37.
    Camara O, Rengsberger M, Egbe A, Koch A, Gajda M, Hammer U et al (2007) The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 18:1484–1492CrossRefPubMedGoogle Scholar
  38. 38.
    Cohen SJ (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213–3221CrossRefPubMedGoogle Scholar
  39. 39.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309CrossRefPubMedGoogle Scholar
  40. 40.
    Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK et al (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30:525–532CrossRefPubMedGoogle Scholar
  41. 41.
    Giordano A, Egleston BL, Hajage D, Bland J, Hortobagyi GN, Reuben JM et al (2013) Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 19:1596–1602CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W et al (2013) Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 32:179–188CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420–1428CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M et al (2011) Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 127:33–41CrossRefPubMedGoogle Scholar
  46. 46.
    Bednarz-Knoll N, Alix-Panabieres C, Pantel K (2012) Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 31:673–687CrossRefPubMedGoogle Scholar
  47. 47.
    Wicha MS (2006) Cancer stem cells and metastasis: lethal seeds—commentary. Clin Cancer Res 12:5606–5607CrossRefPubMedGoogle Scholar
  48. 48.
    Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A et al (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178:989–996CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K et al (2009) Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol 219:287–293CrossRefPubMedGoogle Scholar
  50. 50.
    Molnar B, Ladanyi A, Tanko L, Sreter L, Tulassay Z (2001) Circulating tumor cell clusters in the peripheral blood of colorectal cancer patients. Clin Cancer Res 7:4080–4085PubMedGoogle Scholar
  51. 51.
    Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA et al (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158:1110–1122CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72PubMedGoogle Scholar
  53. 53.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013CrossRefPubMedGoogle Scholar
  54. 54.
    Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK et al (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30:2601–2608CrossRefPubMedGoogle Scholar
  55. 55.
    Alix-Panabieres C, Pantel K (2013) Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59:110–118CrossRefPubMedGoogle Scholar
  56. 56.
    Mathew A, Brufsky AM, Davidson NE (2015) Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res 21:2421–2423Google Scholar
  57. 57.
    Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D et al (2009) Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 11:R59CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR et al (2011) Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 122:356–360CrossRefPubMedGoogle Scholar
  59. 59.
    Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L et al (2011) Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat 128:155–163CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Babayan A, Hannemann J, Spotter J, Muller V, Pantel K, Joosse SA (2013) Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One 8:e75038CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Paoletti C, Muniz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N et al (2015) Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor positive breast cancer. Clin Cancer Res 21: 2487–2498Google Scholar
  62. 62.
    Kalinsky K, Mayer JA, Xu X, Pham T, Wong KL, Villarin E et al (2015) Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients. Clin Transl OncolGoogle Scholar
  63. 63.
    Meng S (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393–9398.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Meng S (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci USA 103:17361–17365CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C et al (2009) Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 118:523–530CrossRefPubMedGoogle Scholar
  66. 66.
    Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C et al (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6:e15624CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Smerage JB, Budd GT, Doyle GV, Brown M, Paoletti C, Muniz M et al (2013) Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. Mol Oncol 7:680–692CrossRefPubMedGoogle Scholar
  68. 68.
    Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M et al (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 16:5233–5243CrossRefPubMedGoogle Scholar
  69. 69.
    Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG et al (2015) Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 21:2771–2779Google Scholar
  70. 70.
    de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P et al (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13:3611–3616CrossRefPubMedGoogle Scholar
  71. 71.
    Payne RE, Yague E, Slade MJ, Apostolopoulos C, Jiao LR, Ward B et al (2009) Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 10:51–57CrossRefPubMedGoogle Scholar
  72. 72.
    Kallergi G, Mavroudis D, Georgoulias V, Stournaras C (2007) Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Mol Med 13:79–88CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA et al (2010) Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 16:1073–1084CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Dawson SJ, Rosenfeld N, Caldas C (2013) Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 369:93–94CrossRefPubMedGoogle Scholar
  75. 75.
    Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985–990CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108–112CrossRefPubMedGoogle Scholar
  77. 77.
    Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ et al (2014) Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 20:2643–2650CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothe F, Ignatiadis M et al (2013) Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting. Br J Cancer 108:1358–1367CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L et al (2015) Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 9:749–757Google Scholar
  80. 80.
    Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC et al (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345:216–220CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Schnipper L (1986) Clinical implications of tumor-cell heterogeneity. N Engl J Med 314:1423–1431CrossRefPubMedGoogle Scholar
  82. 82.
    Hayes DF, Paoletti C (2013) Circulating tumour cells: insights into tumour heterogeneity. J Intern Med 274:137–143CrossRefPubMedGoogle Scholar
  83. 83.
    Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N et al (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134:283–289CrossRefPubMedGoogle Scholar
  84. 84.
    Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R et al (2009) Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 115:581–590CrossRefPubMedGoogle Scholar
  85. 85.
    Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E et al (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U et al (2005) Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43:617–627CrossRefPubMedGoogle Scholar
  87. 87.
    Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF (2008) Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res 10:R69CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G et al (2009) Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11:R39CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ et al (2010) Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 126:669–683CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Breast Cancer Research Foundation 2016

Authors and Affiliations

  1. 1.Department of Internal MedicineComprehensive Cancer Center, University of Michigan Health and Hospital SystemAnn ArborUSA

Personalised recommendations